logo
Evolysse Hyaluronic Acid Filler Review

Evolysse Hyaluronic Acid Filler Review

Cosmopolitan5 days ago
It's not every day a new injectable hits the beauty market, so when I first heard about Evolysse, a new type of filler from Evolus (the makers of Jeuveau, a popular type of Botox), my ears immediately perked up...and then my skin perked up, itching to give it a try. Yes, Evolysse is a filler. The dreaded f-word. But it promises to lead the way in rebranding the way social media has conditioned us to view filler in recent months (that it's bad, unnatural, and that it will leave your face looking puffy if overdone in just the slightest) thanks to a new technology that preserves the molecular structure of hyaluronic acid so it looks smooth and natural once injected.
Intrigued? I was too—and was fortunate enough to get an early sneak peek of the newest FDA-approved injectable to see how it compares to the tried-and-true injectables currently on the market. I'm here to give my honest thoughts after trying it, and help set the record straight on where this injectable fits into your cosmetic treatment routine.
Evolysse is a hyaluronic acid injectable. Hyaluronic acid is a molecule that's naturally occurring in our bodies that, when injected underneath the skin, can smooth out imperfections, add volume to areas of the face, and augment features such as the lips, chin, and jawline. You know how your hyaluronic acid serum makes your skin all plump, bouncy, and firm? When injected properly, hyaluronic fillers basically create that same effect but for the long term.
Hyaluronic acid fillers have been around since the early aughts, but Evolysse is the first real technological innovation in the space in the last decade, says Julie K. Karen, MD, a board-certified dermatologist in New York, NY. "It's a new group of hyaluronic acid fillers that seeks to restore volume and smooth out the lower face in a very natural and smooth way because of the innovative technology by which they're developed,' explains Dr. Karen. Said innovative technology is called Cold-X Technology. It's what sets Evolysse apart from other hyaluronic acid-injectables on the market, and it helps protect the natural structure of the hyaluronic acid molecule.
I'm going to get a little sciencey here, but the gist is that hyaluronic acid molecules are sensitive to warmer temperatures when manufactured for aesthetic use, though all current ones on the market are produced in this manner. When hyaluronic acid-injectables are made at very warm temperatures, it 'denatures the hyaluronic acid,' effectively causing it to break down into shorter fragments, which are then crosslinked to reconnect them for use. 'By processing the Evolysse line at cold, near-freezing temperatures, they preserve the natural structure of hyaluronic acid. This leads to a more natural-looking result, mimicking the actual existence of hyaluronic acid in the skin,' says Dr. Karen. This process also leads to more natural tissue integration and less swelling when the product is injected into the skin.
Right now, Evolysse is FDA-approved to smooth dynamic smile lines and laugh lines in the lower face, though, depending on your provider's expertise, it can be injected off-label into other areas to volumize, smooth, or augment. Currently, the Evolysse line has two different types of filler in the U.S. market: Form and Smooth. 'Evolysse Smooth is softer and more pliable, making it suitable for more superficial lines like those around the mouth, like perioral lines, marionette lines, nasolabial folds,' says Connie Yang, MD, a board-certified dermatologist in New York, NY. 'I have injected Smooth in the lips and seen a beautiful, soft result,' says Dr. Yang. Evolysse Form, on the other hand, is firmer, more robust, and gel-like, making it 'suitable for deeper folds and areas needing more volume (like cheeks, jawline, etc.). It provides more structure and contour, which is great for areas that need more volume restoration and support,' she further explains. This all being said, Dr. Yang says the family of injectables 'are quite versatile and can be used at different depths to address a wide variety of concerns on the face.'
Aside from the fact that it smooths dynamic smile lines and laugh lines, augments, and restores volume to areas of the face, Evolysse doesn't cause the lumps and bumps that can potentially form post-injection. 'One of the adverse effects of hyaluronic acid fillers is sometimes delayed onset of nodules, the little lumps, bumps, or granulomas around where the filler is placed,' explains Dr. Karen. By using Cold-X Technology and maintaining the natural form of hyaluronic acid by not having to crosslink it as much, 'they are finding both in the initial pivotal study, and then in practice, there is basically a nonexistent rate of nodules. That's not to say it can't happen, but in their initial study, no delayed onset nodules formed,' Dr. Karen adds.
As of now, according to that same study, Evolysse is shown to last for one year. It's important to note that the length of the study lasted only for 12 months, and that it's been reported that fillers can remain detectable in the face years longer than initially thought, so it's reasonable to infer that Evolysse lasts just as long as other hyaluronic acid-based injectables on the market in the long term.
Anyone experiencing volume loss, particularly around the lower face, and who wants a natural look is a great candidate. Dr. Karen says both Smooth and Form are great for a highly mobile area, such as the mouth (you're chewing, talking, smiling, etc), because of how natural and delicate the product is. 'If you put something that is too lumpy or clumpy in that area, it may not give you the best result,' she says. Dr. Karen adds that there's really no one who isn't a good candidate, unless someone has major volume loss where their end-game aesthetics goals are not realistic from the use of injectables.
As a beauty editor and self-proclaimed aesthetics guinea pig, I wanted to try Evolysse to fill in some areas of slight volume loss around my mouth that were bugging me. I visited Dr. Karen's office for my Evolysse treatment. After having numbing cream applied to my areas of concern in my lower face and sitting with it for about 10 minutes, Dr. Karen assessed my face, choosing to use Evolysse Form on me. She injected a little bit of Evolysse Form between my upper lip and cheek, the nasolabial fold, and the melolabial fold, or what people call the marionette. She also placed a little in the pre-jowl sulcus, which is that slight divot that people get at the lateral aspect of their chin, along the jawline.
Thanks to the numbing cream, the experience was only very mildly uncomfortable. The whole thing took less than thirty minutes, and I saw the results of the product immediately. Though very subtle, the skin around my lower face looked smoother and slightly plumper.
The immediate results are what Dr. Yang loves about the injectable. 'What's unique about Evolysse is that you can treat to correction, meaning what you see after injection is about what you can expect in the long run. With Cold-X Technology, these fillers do not swell as much as other HAs on the market, which can be a good thing depending on your treatment goals."
Depending on your location, provider, and number of syringes needed, the cost may vary, but the price of Evolysse is comparable to other brands of hyaluronic acid-injectables. You can expect to pay around $900 to $1,500 for a syringe, but even this range may vary. For reference, Dr. Karen does not usually inject more than a syringe or two at a time during an appointment.
While I certainly love the results from my Evolysse appointment and find them to be super natural, it ultimately does not look like I've had filler, which is arguably the whole point. Provided you go to an experienced injector, you Evolysse can definitely refresh your face without making you look overfilled or puffy. I also loved that the effects were instant—so when I left my appointment, I immediately felt good about my results. All in all, Evolysse is another great option to choose from if you're interested in fillers.
Taryn is a beauty writer and editor in digital media with more than 10 years of experience. She has covered the newest and most innovative skincare and beauty products, aesthetic treatments, and plastic surgery trends. Her stories touch on everything from the best products to treat hyperpigmentation to why fat grafting is the better alternative to filler. In addition to Cosmopolitan, she currently contributes to Allure, InStyle, PS (formerly POPSUGAR), Marie Claire, The Zoe Report, and Bustle. In addition to her writing, Taryn directs, produces, and writes short films that have appeared at numerous film festivals around the country. Whenever she has a free moment, you can find her hopping around New York City with her Maltese pup, Bryn, and probably daydreaming about being at the beach. Follow her on Instagram for the latest.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand

Business Upturn

time2 hours ago

  • Business Upturn

Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand

Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) — Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder . This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: FolqsContact Person: David Johnson Email: [email protected] Phone: 800-975-4495Country: United States Website:

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

Yahoo

time5 hours ago

  • Yahoo

Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment

Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy now. On July 29, Bausch Health Companies announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX). The acquisition is valued at ~$63 million upfront with potential for an additional $350 million in sales milestone payments, and will be an all-cash transaction. Bausch Health is acquiring DURECT primarily for its lead asset, called larsucosterol. This novel therapeutic molecule is an epigenetic modulator that the FDA has granted Breakthrough Therapy Designation for the treatment of alcoholic hepatitis/AH, which is a life-threatening form of alcohol-associated liver disease. A closeup of pills in a pharmacy, representing the high quality medications of the company. AH is characterized by severe liver inflammation & necrosis and accounted for ~164,000 hospital admissions in the US in 2021. There are currently no FDA or European Medicines Agency/EMA-approved treatments for the condition. The acquisition of larsucosterol strengthens Bausch Health's commitment to hepatology. Bausch Health plans to use its expertise to advance larsucosterol through a planned Phase 3 program. Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharmaceutical and medical device company that develops, manufactures, and markets products in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, OTC products, aesthetic medical devices, and eye health. DURECT Corporation (NASDAQ:DRRX) is a late-stage biopharmaceutical company that develops epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, such as acute organ injury. While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand
Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand

Associated Press

time5 hours ago

  • Associated Press

Folqs Highlights First-Day, Grass-Fed Colostrum Powder Amid Global Surge in Demand

Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Folqs, a U.S.-based wellness company, introduces new consumer product, Folqs First-Day Colostrum Powder. This positions the company within the growing colostrum supplement sector, which has recently exceeded $3 billion in global market value, according to industry research. The product is formulated from bovine colostrum collected on the first day after birth and sourced exclusively from grass-fed, pasture-raised cows located in the United States. Processing and packaging are conducted domestically at an FDA-registered facility that operates under Current Good Manufacturing Practices (cGMP). This announcement marks Folqs' formal entry into a sector experiencing measurable growth. A 2025 report from Grand View Research estimates the global colostrum market will sustain a compound annual growth rate of approximately 7% through 2030. Concurrently, online search interest in colostrum-related supplements has risen 68% year-over-year, based on recent data from Google Trends. Product Developed for Adults Focused on Dietary Supplementation According to the company, Folqs First-Day Colostrum Powder is unflavoured and designed to dissolve quickly into liquids. It is intended for use by adults who are exploring food-based supplement options. The product contains naturally occurring bioactive compounds found in colostrum, including immunoglobulins and growth factors Folqs has indicated it does not add any artificial ingredients or flavoring agents during production. The colostrum used is collected only after the needs of the newborn calf have been met, under a sourcing policy the company refers to as 'Calf-First.' This policy stipulates that calves receive their full share before any surplus is gathered for human use. Each batch undergoes third-party testing, with screening for microbiological content, heavy metals, and nutritional composition. Documentation of testing is maintained for internal quality control and regulatory compliance. Market Timing Reflects Broader Consumer Shift Toward Food-Based Supplements The decision to launch into the colostrum segment comes at a time when consumer attention to supplement sourcing and transparency has intensified. Data from the Council for Responsible Nutrition (2024) indicates that only 52% of U.S. supplement users consider product labels to be 'very trustworthy.' Folqs' leadership said that these statistics informed its approach to formulation, production, and consumer messaging. 'Consumers are tired of vague 'proprietary blends.' By sharing our lab reports and guaranteeing results, we're setting a new transparency bar for the $3 billion colostrum space,' said David Johnson, Company Spokesperson. Johnson noted that Folqs will prioritize third-party testing as part of its operational model. 'We've aligned our product development process with the demand for greater transparency in supplement sourcing,' Johnson said. 'Every decision, from raw ingredient origin to packaging, was shaped by current expectations in the space.' Availability and Purchasing Details Folqs First-Day Colostrum Powder is exclusively available through the company's official website, Pricing, serving guidelines, and detailed product specifications are provided on the site. No retail or third-party distribution agreements were announced at the time of release. The product is offered under a customer refund policy referred to as the 90-Day Money-Back guarantee, allowing purchasers to request a refund if unsatisfied. Folqs stated that this policy was introduced to address consumer hesitations common in the dietary supplement category. No Comparisons or Claims Made Against Competing Brands Under established content distribution standards, Folqs has not made any comparative statements regarding other colostrum products on the market. Folqs emphasized that its entry into the colostrum market is grounded in sourcing and production controls, rather than marketing-driven distinctions. It has not used or referenced any competing companies or their product names in its communications. Regulatory and Testing Framework The colostrum is processed in a facility that meets federal registration and cGMP compliance criteria. Third-party laboratories are used to conduct batch testing. All production occurs within the United States, and the company maintains that its supply chain remains fully domestic at this time. No claims have been made about the product's ability to prevent, treat, or cure any medical condition. The company has not submitted its product for review by the Food and Drug Administration, as it is sold as a dietary supplement and not a drug. About Folqs Folqs is a privately held wellness company headquartered in Wilmington, Delaware. It specializes in sourcing and manufacturing food-based supplements. The company's operational focus includes domestic production, third-party testing, and ingredient transparency. Folqs First-Day Colostrum Powder is its first product offering. Media Contact Company Name: Folqs Contact Person: David Johnson Email: [email protected] Phone: 800-975-4495 Country: United States Website: Media Contact Company Name: Folqs Contact Person: David Johnson Email: [email protected] Phone: 800-975-4495 Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store